Annals of the Rheumatic Diseases (ARD)

is a leading rheumatology journal from EULAR, publishing original research, reviews and recommendations

Impact Factor: 20.3
Citescore: 35
All metrics >>

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

Free lay summaries are provided for selected research articles and all EULAR recommendations. You can keep up with the latest news via X and Facebook.

Listen to the ARD Podcast and subscribe in all podcast platforms, including Apple Podcasts, Amazon Music and Spotify.

Editor-in-Chief: Professor Josef Smolen, Medical University of Vienna, Austria
Editorial team

ARD is a Plan S compliant Transformative Journal.

Current Issue

Latest EULAR Recommendations

Treatment of systemic sclerosis

EULAR recommendations for the treatment of systemic sclerosis: 2023 update

Involvement of patient research partners in rheumatology research

EULAR recommendations for the involvement of patient research partners in rheumatology research: 2023 update

Management of psoriatic arthritis with pharmacological therapies

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

3D rendered photo of rheumatological disease affecting the hand

Imaging in diagnosis and management of CiAs in clinical practice

2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice

Authors

Annals of the Rheumatic Diseases will be published by Elsevier from January 2025. All new manuscript submissions should be submitted online at https://www.editorialmanager.com/ards/default2.aspx.

Author information Submit a paper

Latest Articles

Recommendation:

Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults

28 November 2024

Letter:

CD-19 CAR-T cells for polyrefractory rheumatoid arthritis

27 November 2024

Rheumatoid arthritis:

Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial

27 November 2024

Correction:

Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

27 November 2024

Systemic lupus erythematosus:

Pharmacodynamics of the S1P1 receptor modulator cenerimod in a phase 2b randomised clinical trial in patients with moderate to severe SLE

24 November 2024

Articles by Topic

View full list

Recommendations

The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field.

All EULAR recommendations are free to access.

Each recommendation also has an accompanying lay summary, which is also free to access.

Video Abstract

m6A RNA methylation controls salivary gland epithelial cell function and has a protective role in Sjögren’s disease

18 September 2024

Conclusions: Impairment of m6A modifications in SGEC in response to inflammatory triggers favour the formation of dsRNA, potentially amplifying the interferon loop and contributing to SjD pathogenesis.

Find out more